Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase II Basket Study of a hypoMEThylating Agent Oral Azacitidine and DURvalumab (MEDI4736) (Anti-PDL1) in Advanced Solid Tumors (METADUR)

NCT02811497 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT02811497
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02811497 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase II Basket Study of a hypoMEThylating Agent Oral Azacitidine and DURvalumab (MEDI4736) (Anti-PDL1) in Advanced Solid Tumors (METADUR)
Lead sponsor
University Health Network, Toronto
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2016
Completion date
August 4, 2020
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

estrogen receptor positive and her2 negative breast cancer, microsatellite stable colorectal carcinoma, platinum resistant epithelial ovarian cancer type ii